Ligand Pharmaceuticals Incorporated
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
Bought 3.81M
Granted 2.4K · Bought 350.0K · Sold 5.72M
Bought 39.6K · Sold 950.4K
Bought 1.34M · Sold 5.96M
Granted 81.4K · Bought 3.04M · Sold 3.99M
Granted 1.21M · Bought 22.4K · Sold 401.7K
Granted 289.4K · Bought 32.0K · Sold 41.3K
Granted 144.2K · Sold 159.0K
Granted 445.6K · Bought 4.6K · Sold 226.2K
Granted 104.5K · Bought 68.6K · Sold 259.6K
Granted 95.8K · Bought 11.3K · Sold 5.3K
Granted 183.5K · Bought 500 · Sold 95.7K
Granted 92.3K · Bought 169 · Sold 70.7K
Granted 115.1K · Bought 37.0K · Sold 48.6K
Granted 85.4K · Sold 35.8K
Granted 25.0K · Sold 6.0K
Granted 12.4K
Granted 77.5K · Bought 4.0K · Sold 39.3K
Granted 62.5K · Bought 10.0K · Sold 37.8K
Granted 61.9K · Bought 21.0K · Sold 46.9K
Granted 84.7K · Bought 1.5K · Sold 41.8K
Granted 188.3K · Sold 102.3K
Granted 301.8K · Bought 1.4K · Sold 199.3K
Granted 45.0K · Sold 45.0K
Granted 74.0K · Sold 3.2K
Granted 15.0K
Granted 3.7K
Granted 10.2K · Sold 6.5K
Granted 10.0K
Granted 10.0K
Granted 10.0K
Granted 15.2K · Sold 7.5K
Granted 2.4K
Granted 41.7K · Sold 41.7K
Granted 10.0K
Granted 50.0K · Sold 50.0K
Granted 5.6K
Granted 14.6K · Bought 98 · Sold 14.3K
Granted 3.9K
Granted 2.4K
Granted 28.5K · Sold 32.2K
Granted 2.2K
Granted 75.8K · Sold 75.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +4 co-filersReporting owner · 70 transactions | — | 49.07Mas of Jan 2009 | — | 3.81M | — |
| Loeb Daniel SFormer Director (1) · 5 transactions | — | 9.55Mas of Mar 2007 | 2.4K | 350.0K | 5.72M |
| Biotechnology Value Fund II LP +6 co-filersSee Explanation of Responses, 10% owner · 20 transactions | — | 2.53Mas of Feb 2014 | — | 39.6K | 950.4K |
| Biotechnology Value Fund II LP +5 co-filersSee Explanation of Responses · 68 transactions | — | 2.52Mas of Mar 2014 | — | 1.34M | 5.96M |
| Knott David MDirector · 174 transactions | — | 1.34Mas of Aug 2015 | 81.4K | 3.04M | 3.99M |
| Higgins John LDirector · 155 transactions | — | 417.7Kas of Dec 2022 | 1.21M | 22.4K | 401.7K |
| Davis Todd CChief Executive Officer, Director · 75 transactions | — | 199.4K | 289.4K | 32.0K | 41.3K |
| Maier Paul VSr. V-P, CFO · 111 transactions | — | 191.0Kas of Nov 2006 | 144.2K | — | 159.0K |
| Foehr Matthew WFormer Executive Officer · 133 transactions | — | 162.2Kas of Nov 2022 | 445.6K | 4.6K | 226.2K |
| Aryeh JasonDirector · 119 transactions | — | 120.6K | 104.5K | 68.6K | 259.6K |
| Meglasson MartinV-P, Discovery Research · 12 transactions | — | 102.3Kas of May 2010 | 95.8K | 11.3K | 5.3K |
| Korenberg Matthew EPresident & COO · 93 transactions | — | 51.0Kas of Sep 2024 | 183.5K | 500 | 95.7K |
| DeSilva Nishan MVP, Finance & Strategy and CFO · 17 transactions | — | 43.2Kas of May 2015 | 92.3K | 169 | 70.7K |
| Kozarich John WDirector · 136 transactions | — | 42.6K | 115.1K | 37.0K | 48.6K |
| Reardon AndrewCLO & Secretary · 70 transactions | — | 41.6K | 85.4K | — | 35.8K |
| Dziewanowska Zofia EVP, Clinical Research · 3 transactions | — | 34.0Kas of Feb 2009 | 25.0K | — | 6.0K |
| Perry Jeffrey RDirector · 3 transactions | — | 34.0Kas of May 2008 | 12.4K | — | — |
| Sabba Stephen LDirector · 45 transactions | — | 33.6K | 77.5K | 4.0K | 39.3K |
| Lamattina John LDirector · 55 transactions | — | 31.1K | 62.5K | 10.0K | 37.8K |
| Patel SunilFormer Director · 42 transactions | — | 28.8Kas of Nov 2022 | 61.9K | 21.0K | 46.9K |
| Espinoza OctavioChief Financial Officer · 78 transactions | — | 26.7K | 84.7K | 1.5K | 41.8K |
| Sharp John PVP Finance and CFO · 40 transactions | — | 25.0Kas of Feb 2014 | 188.3K | — | 102.3K |
| Berkman Charles SFormer Executive Officer · 140 transactions | — | 23.8Kas of Nov 2022 | 301.8K | 1.4K | 199.3K |
| Crouch TaylorSr. V-P, Ops & Pres. Int'l · 11 transactions | — | 18.2Kas of Dec 2006 | 45.0K | — | 45.0K |
| Kazmi SyedVP, Bus. Dev. & Strategic Plan · 13 transactions | — | 18.2Kas of Feb 2012 | 74.0K | — | 3.2K |
| Burakoff Steven JDirector · 2 transactions | — | 15.0Kas of May 2009 | 15.0K | — | — |
| Rocca Michael ADirector · 1 transaction | — | 11.7Kas of Jan 2006 | 3.7K | — | — |
| Haas JasonDirector · 9 transactions | — | 11.4K | 10.2K | — | 6.5K |
| Greetham Elizabeth MDirector · 2 transactions | — | 10.0Kas of May 2008 | 10.0K | — | — |
| Ligand Pharmaceuticals IncDirector · 1 transaction | — | 10.0Kas of Aug 2008 | 10.0K | — | — |
| Peacock BruceDirector · 1 transaction | — | 10.0Kas of Dec 2008 | 10.0K | — | — |
| Gray Nancy RyanDirector · 14 transactions | — | 8.9K | 15.2K | — | 7.5K |
| Peck Carl CDirector · 1 transaction | — | 8.4Kas of Jan 2006 | 2.4K | — | — |
| Negro-Vilar AndresExe V-P, R & D, CSO · 12 transactions | — | 8.3Kas of Dec 2006 | 41.7K | — | 41.7K |
| Blissenbach Henry FDirector · 6 transactions | — | 6.5Kas of Apr 2007 | 10.0K | — | — |
| Groves Eric SV-P, Project Management · 6 transactions | — | 5.1Kas of Dec 2006 | 50.0K | — | 50.0K |
| Zimmermann MartineDirector · 7 transactions | — | 5.1K | 5.6K | — | — |
| Herman Melanie JDirector of Accounting · 27 transactions | — | 3.5Kas of Jun 2016 | 14.6K | 98 | 14.3K |
| Boyce SarahFormer Director · 5 transactions | — | 2.9Kas of Nov 2022 | 3.9K | — | — |
| Roberts BrigetteDirector · 1 transaction | — | 2.4Kas of Jan 2006 | 2.4K | — | — |
| Broaddus Warner RV-P, Gen. Counsel & Secy. · 17 transactions | — | 1.6Kas of Nov 2006 | 28.5K | — | 32.2K |
| Cochran Jennifer R.Former Director · 3 transactions | — | 1.2Kas of Nov 2022 | 2.2K | — | — |
| Petttit William ASr. V-P, HR and Administration · 22 transactions | — | 889as of Dec 2006 | 75.8K | — | 75.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -9.92M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.